Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise for leukemia relapse after transplant

NCT ID NCT02684162

First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 29 times

Summary

This study tested a drug called guadecitabine combined with donor white blood cell infusions in 55 adults whose leukemia or MDS came back after a stem cell transplant. The goal was to see if the drug could help the donor cells fight the cancer more effectively. The treatment aims to control the disease, but lifelong monitoring and potential ongoing therapy may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.